Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Monath

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
The Journal of Infectious Diseases|January 11, 2011
Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccinationHeidi L Smith, Thomas P Monath, Pamela Pazoles, et al.
Lancet (London, England)|April 27, 2016
Yellow fever vaccine supply: a possible solutionThomas P Monath, Jack P Woodall, Duane J Gubler, et al.
Vaccine|August 19, 2004
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccineDavid W C Beasley, Li Li, Miguel T Suderman, et al.
Vaccine|November 27, 2002
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pyloriStavros Sougioultzis, Cynthia K Lee, Mazen Alsahli, et al.
Vaccine|April 20, 2005
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adultsAndrew W Artenstein, Casey Johnson, Thomas C Marbury, et al.
The Journal of Infectious Diseases|October 11, 2003
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigenThomas P Monath, Farshad Guirakhoo, Richard Nichols, et al.
Vaccine|January 23, 2002
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infectionsThomas P Monath, Karen McCarthy, Philip Bedford, et al.
The American Journal of Tropical Medicine and Hygiene|August 31, 2002
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trialThomas P Monath, Richard Nichols, W Tad Archambault, et al.
Gastroenterology|March 15, 2005
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrheaStavros Sougioultzis, Lorraine Kyne, Denise Drudy, et al.
The Lancet. Infectious Diseases|July 30, 2011
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow FeverEmily S Jentes, Gilles Poumerol, Mark D Gershman, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
The Journal of Infectious Diseases|January 11, 2011
Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccinationHeidi L Smith, Thomas P Monath, Pamela Pazoles, et al.
Lancet (London, England)|April 27, 2016
Yellow fever vaccine supply: a possible solutionThomas P Monath, Jack P Woodall, Duane J Gubler, et al.
Vaccine|August 19, 2004
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccineDavid W C Beasley, Li Li, Miguel T Suderman, et al.
Vaccine|November 27, 2002
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pyloriStavros Sougioultzis, Cynthia K Lee, Mazen Alsahli, et al.
Vaccine|April 20, 2005
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adultsAndrew W Artenstein, Casey Johnson, Thomas C Marbury, et al.
The Journal of Infectious Diseases|October 11, 2003
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigenThomas P Monath, Farshad Guirakhoo, Richard Nichols, et al.
Vaccine|January 23, 2002
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infectionsThomas P Monath, Karen McCarthy, Philip Bedford, et al.
The American Journal of Tropical Medicine and Hygiene|August 31, 2002
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trialThomas P Monath, Richard Nichols, W Tad Archambault, et al.
Gastroenterology|March 15, 2005
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrheaStavros Sougioultzis, Lorraine Kyne, Denise Drudy, et al.
The Lancet. Infectious Diseases|July 30, 2011
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow FeverEmily S Jentes, Gilles Poumerol, Mark D Gershman, et al.
Pageof 14